Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in β-tubulin isotype expression

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 3865-3870

  Wehbe, H ^a   Kearney, Christopher M ^a   Pinney, K G ^a  

^a BAYLOR UNIVERSITY   (United States)

Author keywords

tubulin isotypes; Combretastatin A 4; Microtubules; Resistance

Indexed keywords

BETA TUBULIN; CELL PROTEIN; CISPLATIN; COLCHICINE; COMBRETASTATIN A1 PHOSPHATE; PACLITAXEL; VERAPAMIL; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LUNG CARCINOMA; MICROTUBULE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PROTEIN ISOFORMS; STILBENES; TUBULIN; VINBLASTINE;

EID: 27944510554     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
2. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996.
3. Nogales E: Structural insights into microtubule function. Ann Rev Biochem 69: 277-302, 2000.
4. Rai SS and Wolff J: Localization of the vinblastine-binding site on β-tubulin. J Biol Chem 277: 14707-14711, 1996.
5. Nogales E, Whittaker M, Milligan RA and Downing KH: High-resolution model of the microtubule. Cell 96: 79-88, 1999.
6. Nogales E, Wolf SG and Downing KH: Structure of the αβ tubulin dimer by electron crystallography. Nature 391: 199-202, 1998.
7. Bai RL, Pei XF, Boye O, Getahun Z, Grover S, Bekisz J, Nguyen NY, Brossi A and Hamel E: Identification of cysteine 354 of β-tubulin as part of the binding site for the A ring of colchicines. J Biol Chem 277: 12639-12645, 1996.
8. Uppuluri S, Knipling L, Sackett DL and Wolff J: Localization of the colchicine-binding site of tubulin. Proc Natl Acad Sci USA 90: 11598-11602, 1993.
9. Sullivan KF: Structure and utilization of tubulin isotypes. Ann Rev Cell Biol 4: 687-716, 1988.
10. Sullivan KF and Cleveland DW: Identification of conserved isotype-defining variable region sequences for four vertebrate β tubulin polypeptide classes. Proc Natl Acad Sci USA 83: 4327-4331, 1986.
11. Cowen NJ and Dudley L: Tubulin isotypes and the multigene tubulin families. Int Rev Cytol 85: 147-173, 1983.
12. Banerjee A and Ludueña RF: Kinetics of colchicine binding to purified β-tubulin isotypes from bovine brain. J Biol Chem 267: 13335-13339, 1992.
13. Derry WB, Wilson L, Khan IA, Ludueña RF and Jordan MA: Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 36: 3554-3562, 1997.
14. III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18: 173-182, 1993.
15. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD and Horwitz SB: Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269-31275, 1995.
16. Jaffrézou J-P, Dumontet C, Derry WB, Durán G, Chen G, Tsuchiya E, Wilson L, Jordan MA and Sikic BI: Novel mechanism of resistance to paclitaxel (taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 7: 517-527, 1995.
17. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR: Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566, 1996.
18. III isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta 1395: 237-245, 1998.
19. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD and Haber M: Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 61: 5803-5809, 2001.
20. Burkhart CA, Kavallaris M and Horwitz SB: The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471: O1-O9, 2001.
21. Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
22. Pettit GR, Cragg GM, Herald DL, Schmidt JM and Lohavanijay P: Isolation and structure of combretastatin. Can J Chem 60: 1374-1376, 1982.
23. Pettit GR, Cragg GM and Singh SB: Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 50: 386-391, 1987.
24. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM and Hogan F: Antineoplastic agents. 291. Isolation and synthesis of combretastatin A-4, A-5, and A-6(1a). J Med Chem 38: 1666-1672, 1995.
25. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45: 209-211, 1989.
26. Pettit GR, Singh SB, Niven ML, Hamel E and Schmidt JM: Isolation, structure, and synthesis of combretastatin A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50: 119-131, 1987.
27. Pettit GR, Singh SB, Schmidt JM, Niven ML, Hamel E and Lin CM: Isolation, structure, synthesis and antimitotic properties of combretastatins B-3 and B-4 from caffrum. J Nat Prod 57: 517-527, 1988.
28. Hamel E and Lin CM: Interactions of combretastatin: a new plant-derived antimitotic agent, with tubulin. Biochem Pharmacol 32: 3864-3867, 1983.
29. Chu JJ, Chiang C-D, Rao CS, Chang W-M and Lai Y-K: Establishment and characterization of a paclitaxel-resistant human non-small cell lung cancer cell line. Anticancer Res 20: 2449-2456, 2000.
30. Han EK, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, Rosenberg SH and Ng S-C: Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 36: 1565-1571, 2000.
31. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immuno Methods 65: 55-63, 1983.
32. Minotti AM, Barlow SB and Cabral F: Resistance to antimitotic drugs in Chinese hamster ovary cell correlates with changes in the level of polymerized tubulin. J Biol Chem 266: 3987-3994, 1991.
33. Seve P and Dumontet C: Chemoresistance in non-small cell lung cancer. Curr Med Chem Anti-Canc Agents 5: 73-88, 2005.
34. Berrieman HK, Lind MJ and Cawkwell L: Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 5: 158-164, 2004.
35. Hari M, Wang Y, Veeraraghavan S and Cabral F: Mutations in α- and β-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2: 597-605, 2003.
36. Khan IA and Luduena RF: Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Invest New Drugs 21: 3-13, 2003.
37. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427, 2004.
38. Ohta S, Nishio K, Kubo S, Nishio M, Ohmori T, Takahashi T and Saijo N: Characterization of a vindesine-resistant human small-cell lung cancer cell line. Br J Cancer 68: 74-79, 1993.
39. Sirotnak FM, Dananberg KD, Chen J, Fritz F and Danenberg PV: Markedly decreased binding of vincristine to tubulin in Vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of α and β tubulin isoforms. Biochem Biophys Res Commun 269: 21-24, 2000.